Healthcare Industry News: Mobetron
News Release - September 19, 2006
IntraOp Medical Corporation Delivers Mobetron, Advanced Intraoperative Electron Radiation Therapy System, to St. Augustinius Hospital in BelgiumKey Mobetron Benefits Include Increased Survival Rates, Better Local Tumor Control, Shorter Treatment Cycles, and Fewer Side Effects
SUNNYVALE, Calif.--(HSMN NewsFeed)--Sept. 19, 2006--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced it has delivered Mobetron® to St. Augustinius Hospital in Belgium. A fully portable, self-shielding device, Mobetron directly delivers intraoperative electron radiation therapy ("IOERT") to patients safely and quickly as they undergo surgery. St. Augustinius, which has the first IOERT program in Belgium, will use Mobetron to treat a variety of tumors, including early-stage breast cancer. The unit will begin patient treatment in late Fall 2006.
St. Augustinius is a 600-bed hospital located in Antwerp, Belgium that specializes in treating patients with innovative high-technology medical equipment. The hospital uses a comprehensive, multidisciplinary approach to treating cancer, integrating surgery, radiation therapy and chemotherapy treatments, as appropriate. St. Augustinius treats about 2,500 cancer patients per year.
Donald A. Goer, President and CEO of IntraOp Medical Corporation said, "Delivering another Mobetron is always exciting, but it is especially gratifying when that Mobetron provides the first intraoperative electron radiation therapy program in the country. This is just further evidence that Mobetron is gaining greater acceptance worldwide. We look forward to working closely with St. Augustinius and to providing the most advanced medical technology available to effectively and efficiently treat cancer."
With Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Hospitals can wheel Mobetron between existing operating rooms without the costly renovations required to accommodate traditional radiation therapy devices. Key patient benefits of this early and powerful start to radiation therapy include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects.
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.